New Market Research Report: OpportunityAnalyzer: Axial Spondyloarthritis

From: Fast Market Research, Inc.
Published: Sun Oct 18 2015


Ankylosing Spondylitis (AS) is an autoimmune disease that causes inflammation of the sacroiliac joint accompanied by pain and stiffness of the lower back, which typically gets better with exercise. Ankylosis (fusion) of the spine is typically a late-stage complication and has been nicknamed "bamboo spine", due to its appearance on X-ray. It is now recognized that the pathological changes leading to ankylosis develop over time, and an early stage of the disease, known as non-radiographic axial spondyloarthritis (nr-axSpA) is characterized by the same symptoms of inflammatory back pain without radiographic changes observed by X-ray. Together, AS and nr-axSpA are known as axial spondyloarthritis (axSpA). AS and nr-axSpA affect roughly 1.3 million and 700,000 individuals, respectively, in the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) covered in this report and the prevalence is expected to grow mainly due to changes in diagnosis rates. The anti-TNFs have been effective in treating the signs and symptoms of axSpA, however, there is a lack of effective therapeutic classes, and no treatment options for patients who have failed anti-TNF therapy, representing a key unmet need and opportunities for drug developers.

Full Report Details at
- http://www.fastmr.com/prod/1058673_opportunityanalyzer_axial.aspx?afid=301

Highlights

Key Questions Answered

* What are the preferred anti-TNFs for and how will competition from pipeline agents and biosimilars affect sales? Are rheumatologists across the 7MM expected to prescribe biosimlars for axSpA?
* Will there be strong uptake of pipeline agents and how will Novartis's Cosentyx, J&J's Stelara, and Celgene's Otezla be used in the clinic?
* According to key opinion leaders (KOLs), what are the most important unmet needs in axSpA? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?
* How will disease awareness change over the forecast period and will this affect diagnosis?
* How is non-radiographic axial spondyloarthritis (nr-axSpA) treated and will the diagnosis and treatment change over the next decade? Which drugs are expected to gain label expansions into nr-axSpA?

Key Findings

* Increased diagnosis and treatment are key drivers in the axSpA market.
* Novartis's Cosentyx and J&J's Stelara will address the unmet need for drugs with novel MOAs and pose a threat to anti-TNFs, which are currently the only therapeutic class beyond NSAIDs.
* Label expansions into AS and nr-axSpA are expected to be an increasingly popular life-cycle management strategy for pharmaceutical companies developing drugs that target the immune system.
* Biosimilars are expected to change the landscape for axSpA and will create pricing pressure in the market.

Report Scope

* Overview of axial spondyloarthritis (axSpA), including etiology, pathophysiology, symptoms, and current treatment recommendations.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020 - Event-Driven Update
- OpportunityAnalyzer: Myasthenia Gravis - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Celiac Disease - Opportunity Analysis and Forecast to 2023
- OpportunityAnalyzer: Acromegaly and Gigantism - Opportunity Analysis and Forecast to 2018
- OpportunityAnalyzer: Allergic Rhinitis: Allergen-Specific Immunotherapy - Opportunity Analysis and Forecast to 2018

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »